Shield Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SHIEF research report →
About the company
Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/Feraccru, offers an innovative, non-salt-based oral treatment specifically for adults suffering from iron deficiency, irrespective of whether anemia is present. Furthermore, the company is advancing PT20, a pioneering iron-based phosphate binder that has successfully concluded its pivotal Phase II trials for managing hyperphosphatemia in individuals with chronic kidney disease.
- CEO
- Anders Lundstrom
- IPO
- 2019
- Employees
- 63
- HQ
- Gateshead, GB
Price Chart
- Market Cap
- $85.56M
- P/E
- -4.72
- P/S
- 1.72
- P/B
- -5.79
- EV/EBITDA
- -11.61
- Div Yield
- 0.00%
- Gross Margin
- 44.16%
- Op Margin
- -20.44%
- Net Margin
- -35.72%
- ROE
- 121.87%
- ROIC
- -69.31%
- Revenue
- $50.81M · 26.19%
- Net Income
- $-18,047,645 · 46.93%
- EPS
- $-0.02 · 45.33%
- Op Income
- $-10,310,311
- FCF YoY
- 3.78%
- 52W High
- $0.17
- 52W Low
- $0.04
- 50D MA
- $0.10
- 200D MA
- $0.12
- Beta
- 1.76
- Avg Volume
- 325
Get TickerSpark's AI analysis on SHIEF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SHIEF coverage
Recent articles, reports, and earnings notes.
No research on SHIEF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SHIEF report →Similar companies
Peers in the same neighborhood.